Dr. Nazneen Dewji is President and CEO of Cenna Biosciences Inc. in La Jolla, CA and an Associate Adjunct Professor of Medicine at the UC San Diego. Nazneen was educated at the University of London, where she earned her B.Sc. (Hons.) and Ph.D. degrees. In 1986 she joined the department of Medicine at UCSD. Since then she has worked on the molecular and cellular mechanisms in Alzheimer's disease (AD). The discoveries made in her laboratory at UCSD have supported the development of new disease-modifying drug candidates for the treatment of AD. These are currently being developed at Cenna Biosciences Inc, a company that she, and her colleague the late Dr. S. J. Singer, founded in 2006. Cenna’s proprietary technology addresses the underlying cause of the disease, the inappropriate deposition of the toxic species Aß. The Company has developed novel targets and is developing several lead peptide and small molecule compounds as disease-modifying drug candidates for the treatment of AD.